|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1155 F STREET, NW, #1150 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Princeton |
State | NJ |
Zip Code | 08540 |
Country | USA |
|
5. Senate ID# 284790-12
|
||||||||
|
6. House ID# 369030000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Michael Mawby, Chief Government Affairs Officer |
Date | 07/17/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues regarding comparative effectiveness, implementation of Physician Payment Sunshine provisions and Prescription Drug Sample reporting provisions; S.3187 FDA Safety and Innovation Act (PDUFA V); H.R. 4274 Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act;
H.R. 3026 Safeguarding America's Pharmaceuticals Act of 2011; Pharmaceutical Traceability Enhancement Code (Rx TEC) Act; H.R. 5973 FY2013 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (FDA funding); 340B
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Supporting increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program, Special Diabetes Program reauthorization, National Prevention Strategy, Medicaid Quality Measures,
Medicare Annual Wellness Visit, ACOs (related to Medicare Share Savings Program), Coverage of Preventive Services under ACA, HHS Strategic Plan, HHS Multiple Chronic Conditions Framework, National Quality Strategy, Prevention and Public Health Fund, Diabetes Prevention Issues in a Survey of Primary Care Physicians, Adequate Inclusion of Diabetes Care in the Essential Health Benefits Package, IOM Committee on Valuing Community-Based Non-Clinical Prevention Policies and Wellness Strategies, DOL Survey of Employer-Sponsored Health Insurance Coverage, CDC National Survey of Primary Care Policies for Managing Patients with Higher Blood Pressure, High Cholesterol, or Diabetes (NSPCP); H.R. 2954, the Health Equity and Accountability Act of 2011; HR 2960 National Diabetes Clinical Care Commission Act; S. 1559 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2012 on National Diabetes Prevention Program; CMS Obesity Intervention; Healthy People 2020 Abstract; CMS CLIA Program & HIPAA Privacy Rule Patient Access to Test Reports; AHRQ regarding the USPSTF recommendation on screening and management of obesity in adults; PCORI Draft Research Agenda
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Labor - Dept of (DOL), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: biosimilar provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S. 3295 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program); Issues related to modernizing cost estimates with respect to preventive health legislation (scoring) and National Diabetes Prevention Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; CMS Proposed Coverage Decision Memorandum for Intensive Behavioral Therapy for Obesity; Medicare Diabetes Screening; HR 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Medicaid coverage of obesity counseling and expanding provider type;
Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 (deficit reduction)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
S. 1002 SAFE DOSES Act and HR 4223 Safe Doses Act (Modernizing criminal laws concerning theft of medical products)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 436 Protect Medical Innovation Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Pacific Partnership (TPP): biosimilar provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Moriah |
Merkel |
|
|
|
Christopher |
McGowen |
|
|
|
Shaylah |
Nunn |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
9 |
|
||||||
2 |
|
10 |
|
||||||
3 |
|
11 |
|
||||||
4 |
|
12 |
|
||||||
5 |
|
13 |
|
||||||
6 |
|
14 |
|
||||||
7 |
|
15 |
|
||||||
8 |
|
16 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
Novo Nordisk Fonden (Foundation) |
|
|
0.00 | 25.5 % | ||||||||||
Novo A/S |
|
|
0.00 | 25.5 % | ||||||||||
Novo Nordisk A/S |
|
|
0.00 | 100 % |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 9 | 17 |
2 | 10 | 18 |
3 | 11 | 19 |
4 | 12 | 20 |
5 | 13 | 21 |
6 | 14 | 22 |
7 | 15 | 23 |
8 | 16 | 24 |